Stock SNNAQ SIENNA BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Sienna Biopharmaceuticals, Inc.

Equities

SNNAQ

US82622H1086

Delayed OTC Markets
Other stock markets
 09:46:25 10/05/2024 pm IST 		5-day change 1st Jan Change
0.000001 USD 0.00% Intraday chart for Sienna Biopharmaceuticals, Inc. 0.00% 0.00%
2021 Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc. CI
2021 Avro Life Sciences, Inc. entered into an agreement to acquire Certain Assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $0.1 million. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.
CI
Avro Life Sciences, Inc. entered into an agreement to acquire Certain Assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $0.1 million.
CI
Sebacia, Inc. completed the acquisition of all assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q).
CI
Motion For Case Conversion Approved for Sienna Biopharmaceuticals, Inc.
CI
Sienna Biopharmaceuticals, Inc.(OTCPK:SNNA.Q) dropped from NASDAQ Composite Index
CI
Motion for Case Conversion Filed by Sienna Biopharmaceuticals, Inc.
CI
SIENNA BIOPHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.
CI
Sebacia, Inc. entered into a sale purchase agreement to acquire all assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $1.7 million.
CI
Notice of Selection of Successful Bidder Filed by Sienna Biopharmaceuticals, Inc.
CI
Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures
GL
Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice
GL
Bidding Procedure Approved for Sienna Biopharmaceuticals, Inc.
CI
Sienna Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
CI
Motion for Asset Sale Filed by Sienna Biopharmaceuticals, Inc.
CI
Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair
GL
Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair
CI
Sienna Biopharmaceuticals, Inc.(NasdaqGS:SNNA) dropped from S&P Global BMI Index
CI
Sienna Biopharmaceuticals, Inc.(NasdaqGS:SNNA) dropped from S&P TMI Index
CI
Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SNNAQ Stock
  4. News Sienna Biopharmaceuticals, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW